Welcome to our dedicated page for Enlivex news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex stock.
Enlivex Therapeutics Ltd. (ENLV) generates news at the intersection of clinical-stage immunotherapy and digital asset treasury management. Company announcements highlight progress in the development of Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state, and its application in moderate-to-severe knee osteoarthritis. Press releases have detailed positive three- and six-month topline data from the ENX-CL-05-001 Phase I/II trial, including clinically meaningful and statistically significant reductions in pain and improvements in function in age-related primary knee osteoarthritis patients.
Investors following ENLV news will also see updates on Enlivex’s adoption of a digital asset treasury strategy centered on the RAIN token. The company reports that RAIN is the primary asset of its digital asset treasury and describes RAIN as the governance and utility token of a fully decentralized predictions and options protocol built on the Arbitrum network. News items have covered a large private placement intended to fund RAIN token accumulation, an exclusive option agreement to purchase RAIN tokens, and the listing of RAIN on major cryptocurrency exchanges such as KuCoin.
Additional ENLV coverage includes SEC-related disclosures, board and governance changes, shareholder communications, and participation in scientific conferences and investor events. Readers can expect articles on clinical data presentations, new patents related to Allocetra™ in osteoarthritis, shareholder letters outlining strategic roadmaps, and virtual webinars or fireside chats with company leadership and external experts. For those tracking both biotechnology developments in knee osteoarthritis and corporate activity around a RAIN-focused digital asset treasury, the Enlivex news feed provides a consolidated view of the company’s key milestones and strategic decisions.
Enlivex Therapeutics (ENLV) announced its Q2 2021 financial results and key clinical updates. The ongoing Phase IIb trial for AllocetraTM in sepsis is anticipated to report top-line results in Q2 2022, with 120-160 patients expected in the study. A Phase IIb trial for AllocetraTM in severe COVID-19 patients is set to start in Q3 2021. Enlivex also plans a Phase Ib trial to evaluate AllocetraTM combined with chemotherapy for solid tumors. Financially, the company posted a net loss of $3.108 million, with cash and marketable securities of $90.6 million to fund operations through 2023.
Enlivex Therapeutics has announced the appointment of Tzvi Palash as Project Lead for the construction of its new cGMP AllocetraTM manufacturing plant. With over 35 years of experience, including roles at Gamida Cell and Protalix Biotherapeutics, Palash is expected to enhance manufacturing capacity for upcoming clinical trials and potential commercialization. AllocetraTM aims to reprogram macrophages, addressing critical health needs in conditions like sepsis and COVID-19, aligning with Enlivex’s goal of leading in cell therapies.
Enlivex Therapeutics (Nasdaq: ENLV) announced that its CEO, Dr. Oren Hershkovitz, will participate in the Improvate Life-Saving Technologies International Conference 2021 on July 22, 2021. Dr. Hershkovitz's interview, scheduled for 5:15 AM EDT, will focus on the company's AllocetraTM macrophage reprogramming cell therapy platform, aimed at addressing life-threatening unmet medical needs. Attendees can access the live broadcast by registering on the conference's website.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced its participation in the ARDS Drug Development Summit on July 15, 2021. The Company will present AllocetraTM, a promising therapy for acute respiratory distress syndrome (ARDS), a condition with limited effective treatments. The inaugural summit aims to address drug development challenges for both COVID-19 and non-COVID-19 related ARDS. AllocetraTM is designed to reprogram macrophages to restore immune balance, potentially serving life-threatening conditions.
Enlivex Therapeutics has announced the initiation of design and construction for a new cGMP manufacturing plant in Israel, aimed at expanding production capacity for its immunotherapy product Allocetra. This facility, initially planned to be 17,000 square feet with potential expansion to 21,500 square feet, will support ongoing and future clinical trials, along with initial commercial production upon regulatory approvals. CEO Oren Hershkovitz emphasized that this expansion is crucial for advancing clinical readiness for sepsis and COVID-19 treatments.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in A.G.P.’s Virtual Summer Healthcare Symposium on June 17, 2021. The event includes 1-on-1 virtual meetings with investors interested in the company’s management team.
Enlivex is developing Allocetra™ as a universal cell therapy aimed at reprogramming macrophages to restore their homeostatic state, potentially addressing various serious conditions, including solid cancers and COVID-19.
Enlivex Therapeutics (Nasdaq: ENLV) announced the issuance of European patent No. 3,258,943 for AllocetraTM, enhancing its intellectual property portfolio. This patent covers a combination immune therapy aimed at controlling cytokine storms associated with CAR-T therapies for cancer. CEO Oren Hershkovitz expressed satisfaction with the patent grant in Europe, reinforcing the potential of Allocetra in cancer treatment. Allocetra is designed to reprogram macrophages to address severe conditions like sepsis, COVID-19, and solid tumors.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced its participation in the Jefferies 2021 Virtual Healthcare Conference on June 4, 2021, at 10:00 EDT. The presentation will be accessible via the conference website.
Enlivex is focused on Allocetra™, a universal cell therapy aimed at reprogramming macrophages to restore immune system balance. This therapy has potential applications in treating solid cancers, sepsis, and COVID-19, targeting unmet medical needs with an innovative immunotherapeutic approach.
Enlivex Therapeutics (Nasdaq: ENLV) announced the issuance of Canadian Patent No. 2,893,962 for its immunotherapy product candidate AllocetraTM, providing additional protection for its pharmaceutical compositions and manufacturing methods. The patent enhances Enlivex's intellectual property portfolio, contributing to its focus on treating life-threatening diseases such as sepsis, COVID-19, and solid tumors. CEO Oren Hershkovitz emphasized the importance of this patent in supporting their clinical development efforts aimed at addressing significant unmet medical needs.
Enlivex Therapeutics has received a $1.1 million grant from the Israel Innovation Authority, bringing its total non-dilutive funding to approximately $6.6 million for clinical trials and product development. This funding supports Enlivex's ongoing Phase IIb clinical trial of Allocetra for treating organ dysfunctions related to sepsis. Allocetra is designed to reprogram macrophages into their homeostatic state to combat severe diseases, including sepsis and COVID-19, addressing unmet medical needs.